3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
270
Head & Neck
32
Gynecologic
17
Genitourinary
16
Tumor-Agnostic
14
Thoracic
14
Other solid neoplasm
13
Breast
9
Dermatologic
8
Endocrine
3
Sarcoma
2
CNS
2
NET
1
Lymphoid
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
lutetium Lu 177 dotatate
29
Magnetic Resonance Spectroscopy
15
Everolimus
10
pembrolizumab
9
Specimen Handling
9
cabozantinib
7
Nivolumab
7
Lutetium-177
6
surufatinib
5
lenvatinib
5
Octreotide
5
Capecitabine
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
olaparib
4
lanreotide
4
gallium Ga 68 dotatate
4
amino-acid, glucose, and electrolyte solution
4
X-Rays
4
Lutetium
4
Ipilimumab
4
Injections
4
Fluorodeoxyglucose F18
4
copper dotatate CU-64
3
atezolizumab
3
Temozolomide
3
Ga(III)-DOTATOC
3
Cyclophosphamide
3
Carboplatin
3
pasireotide
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fluorouracil
×
NET
×
1 year
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled